
Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2016;1(1):1177.DOI: 10.25107/2474-1663-v1-id1177
Two Patients with Advance-Stage Renal Cell Carcinoma Developed Sunitinib-Related Skin Toxicity
Mehmet Cetinkaya, Ozgur Tanriverdi, Hasan Deliktas, Asude Kara, Yelda Dere and Hayrettin Sahin
Department of Urology, Mugla Sitki Kocman University, Turkey
Department of Medical Oncology, Mugla Sitki Kocman University, Turkey
Department of Dermatology, Mugla Sitki Kocman University, Turkey
Department of Pathology, Mugla Sitki Kocman University, Turkey
*Correspondance to: Mehmet Cetinkaya
PDF Full Text Case Report | Open Access
Abstract:
With the current treatment modalities like molecular targeted therapy, general survival rates have increased in patients with advanced-stage renal cell carcinoma. Sunitinib male at is one of these drugs and its most frequently side effects are fatigue, diarrhea, hypertension, stomatitis, and hair hypo-pigmentation. Additionally, various dermatological side-effects may also be seen such as hand-foot syndrome, a yellowish color change to the face, splinter hemorrhage, erythematosus reactions on the trunk, facial edema, facial erythematosus changes, alopecia, acneiform rash on the face and dysesthesia in the scalp. Although sunitinib maleat-related scrotal skin toxicity is extremely rarely seen, it should not be forgotten that this side-effect can be easily managed. Herein, we report two cases with sunitinib maleat-related scrotal skin toxicity, which were diagnosed with advancedstage renal cell carcinoma in this case report.
Keywords:
Sunitinib; Kidney cancer; Scrotal cutaneous toxicity; Molecular targeted therapy
Cite the Article:
Cetinkaya M, Tanriverdi O, Deliktas H, Kara A, Dere Y, Sahin H. Two Patients with Advance-Stage Renal Cell Carcinoma Developed SunitinibRelated Skin Toxicity. Clin Oncol. 2016;1: 1177.
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590